CSL Behring

HAEGARDA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

CSL Behring

Haegarda HCPCS:

J0599

HCPCS Code Descriptor:

Injection, c-1 esterase inhibitor (human), (haegarda), 10 units

Category:

J Code

Haegarda NDCs:

63833-0828-02, 63833-0829-02

Primary Type:

Immunology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Haegarda CPT Codes:

-96372 - Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

-99211 - Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician or other qualified healthcare professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Haegarda:

HAEGARDA is an Immunology drug manufactured by CSL Behring and administered via the Subcutaneous route of administration. The J Code: J0599 is aligned to the drug HAEGARDA.

ACCESS PRICING AND MORE BY REGISTERING

J0599 Added Date:

January 1, 2019

J0599 Effective Date:

January 1, 2022

J0599 Termination Date:

HCPCS Active

Haegarda billing and coding information can be found through Csl Behring at the link below:
Haegarda patient assistance information can be found through CSL Behring at the URL: https://www.cslbehring.com/patients/support-and-assistance
HAEGARDA prescribing information can be found at the link below:
Information regarding HAEGARDA’s side effects can be found at MedlinePlus